India to be concerned in Sputnik V trials


Sandeep Dikshit
Tribune News Service
New Delhi, August 11

India will get a bit of the motion as Russia enters the final mile of manufacturing the world’s first Covid vaccine.

Phase-III medical trials can be held in several international locations, together with India, Saudi Arabia, UAE, Brazil and Philippines. This can be adopted by mass manufacturing in different international locations in partnership with native financing firms.

Phase-III trials to be held in a number of international locations

  • Phase-III trials can be held in numerous international locations, together with India, Saudi Arabia, UAE, Brazil and Philippines

  • This can be adopted by mass manufacturing in partnership with native financing firms

  • India’s Serum Institute, Panacea Biotech, Shanta Biotech and Biological E Limited are in line for taking on manufacturing orders

The international locations recognized embody India, apart from South Korea and Brazil, Saudi Arabia, Turkey and Cuba, mentioned CEO of Russia Direct Investment Fund (RDIF) Kirill Dmitriev.

“The plan is to ramp up the vaccine production to 20 crore doses by the end of 2020, including 30 crore doses in Russia,” mentioned Dmitriev, whose fund is performing a important operate of bankrolling the analysis.

India was among the many first lot of 20 international locations that had expressed curiosity in acquiring the Sputnik V, he added.

India already has had fruitful partnerships up to now with the US, each in provide chain administration and in joint analysis. External Affairs Minister S Jaishankar and US Secretary of State Mike Pompeo have mentioned the necessity to strengthen world pharmaceutical and healthcare manufacturing and provide chains, an space the place Russia doesn’t have conventional experience.



Be the first to comment on "India to be concerned in Sputnik V trials"

Leave a comment

Your email address will not be published.


*


%d bloggers like this: